4-环己基-4-(1,2,4-三唑-1-基甲基)哌啶 | 312638-92-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-环己基-4-(1,2,4-三唑-1-基甲基)哌啶
• 英文名称: 4-cyclohexyl-4-(1H-1,2,4-triazol-1-yl-methyl)piperidine
• 英文别名: 4-cyclohexyl-4-[(1,2,4-triazol-1-yl)methyl]piperidine；4-cyclohexyl-4-[1,2,4]triazole-1-ylmethylpiperidine；4-cyclohexyl-4-[1,2,4]triazol-1-ylmethylpiperidine；4-Cyclohexyl-4-[(1H-1,2,4-triazol-1-yl)methyl]piperidine；4-cyclohexyl-4-(1,2,4-triazol-1-ylmethyl)piperidine
• CAS: 312638-92-9
• 化学式: C₁₄H₂₄N₄
• 分子量: 248.371
• InChiKey: BDAJCEHKRPQTJD-UHFFFAOYSA-N

物化性质

• 沸点：
  401.7±37.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  42.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-环己基-4-(1,2,4-三唑-1-基甲基)哌啶 在 N-甲基吗啉 、 盐酸 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 (2R)-3-(4-chlorophenyl)-1-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-1-oxo-propan-2-amine
  参考文献：
  名称：

  Design and Pharmacology of N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a Potent, Selective, Melanocortin Subtype-4 Receptor Agonist

  摘要：

  Synthetic and natural peptides that act as nonselective melanocortin receptor agonists have been found to be anorexigenic and to stimulate erectile activity. We report the design and development-of 1, a potent, selective (1184-fold vs MC3R, 350-fold vs MC5R), small-molecule agonist of the MC4 receptor. Pharmacological testing confirms the food intake lowering effects of MC4R agonism and suggests another role for the receptor in the stimulation of erectile activity.

  DOI：

  10.1021/jm025539h
• 作为产物：
  描述：

  去甲哌替啶 在 Rh/Al₂O₃ 盐酸 、 lithium aluminium tetrahydride 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-环己基-4-(1,2,4-三唑-1-基甲基)哌啶
  参考文献：
  名称：

  Design and Pharmacology of N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a Potent, Selective, Melanocortin Subtype-4 Receptor Agonist

  摘要：

  Synthetic and natural peptides that act as nonselective melanocortin receptor agonists have been found to be anorexigenic and to stimulate erectile activity. We report the design and development-of 1, a potent, selective (1184-fold vs MC3R, 350-fold vs MC5R), small-molecule agonist of the MC4 receptor. Pharmacological testing confirms the food intake lowering effects of MC4R agonism and suggests another role for the receptor in the stimulation of erectile activity.

  DOI：

  10.1021/jm025539h

文献信息

• OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：Braun Alain

  公开号：US20070149562A1

  公开（公告）日：2007-06-28

  The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

  本发明涉及根据本文所定义的式（I）的化合物，这些化合物是黑色素皮质素受体激动剂，涉及其制备以及在治疗或预防肥胖、糖尿病和可能影响两性的性功能障碍中的治疗用途，治疗心血管疾病，以及抗炎症用途或治疗酒精依赖症。
• [EN] MELANOCORTIN RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE LA MÉLANOCORTINE
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2005047253A1

  公开（公告）日：2005-05-26

  The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

  本发明涉及一种化合物1的公式，以及作为黑色素皮质素受体激动剂的药用盐、水合物、溶剂合物或同分异构体，以及包含该化合物作为活性成分的黑色素皮质素受体激动剂组合物。
• Melanocortin receptor ligands
  申请人：——

  公开号：US20040010010A1

  公开（公告）日：2004-01-15

  The present invention relates to compounds which comprise a 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring. The compounds, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: 1 wherein preferably R is substituted aryl, W 1 is a carbocyclic unit, and W 2 is a heteroatom comprising unit.

  本发明涉及包含一个与取代或未取代的烃基环相连的4-取代哌啶环的化合物。这些化合物，包括所有的对映异构体和二对映异构体形式以及其药用盐，具有以下公式：其中R最好是取代芳基，W1是一个碳环单元，W2是一个含有杂原子的单元。
• [EN] SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS<br/>[FR] DERIVES DE PIPERIDINE ET DE PIPERAZINE SUBSTITUES UTILISES EN TANT QUE MODULATEURS DU RECEPTEUR DE LA MELANOCORTINE-4
  申请人：MYOCONTRACT LTD

  公开号：WO2004083208A1

  公开（公告）日：2004-09-30

  The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders, where the regulation of the MC-4R is involved, can be treated with the compounds of the invention.

  本发明涉及一种新型的替代哌啶和哌嗪衍生物，作为黑色素皮质素-4受体（MC-4R）调节剂。本发明的MC-4R激动剂可用于治疗肥胖、糖尿病和性功能障碍等疾病，而MC-4R拮抗剂可用于治疗癌症恶病质、肌肉消耗、厌食症、焦虑和抑郁等疾病。所有涉及MC-4R调节的疾病和障碍均可使用本发明的化合物治疗。
• Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
  申请人：MyoContract Ltd.

  公开号：EP1460073A1

  公开（公告）日：2004-09-22

  The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes, and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

  本发明涉及作为黑色素皮质素-4受体（MC-4R）调节剂的新型取代哌啶和哌嗪衍生物。本发明的MC-4R激动剂可用于治疗肥胖、糖尿病和性功能障碍等疾病，而MC-4R拮抗剂可用于治疗癌症恶病质、肌肉消耗、厌食症、焦虑和抑郁等疾病。所有涉及MC-4R调节的疾病和障碍均可通过本发明的化合物进行治疗。